The Nucleocapsid Protein Of SARS-CoV-2, Combined With ODN-39M, Is A Potential Component For An Intranasal Bivalent Pancorona Vaccine
Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Lisset Hermida(Centro de Ingeniería Genética y Biotecnología), Laura Lazo(Centro de Ingeniería Genética y Biotecnología), Vivian Huerta(Centro de Ingeniería Genética y Biotecnología), Edith Suzarte(Centro de Ingeniería Genética y Biotecnología), Yasser Perera(Construction Development (Qatar)), Panchao Ai(Zhejiang Yongning Pharma (China)), Gerardo Guillén(Hunan City University), A.M. Martin(Institut thématique Génétique, génomique et bioinformatique), Ricardo Silva(Centro de Ingeniería Genética y Biotecnología), Rong Chen(Zhongda Hospital Southeast University), Ke Yang(Northwestern Polytechnical University), Alexis Musacchio(Instituto Cajal), Changyuan Tan(Zhejiang Yongning Pharma (China))
Cited by 3
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139